All the news Showing 10 of 44 articles from: Genotype 3Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV Bristol-Myers Squibb press release / 01 February 2016 Daclatasvir and sofosbuvir with ribavirin cures 90% of people with genotype 3 hepatitis C Liz Highleyman / 24 November 2015 An all-oral combination of daclatasvir, sofosbuvir and ribavirin taken for 12 or 16 weeks led to high sustained virological response rates for people with hard-to-treat hepatitis C virus (HCV) genotype 3 and advanced ... Daclatasvir plus sofosbuvir works well for people with genotype 3 hepatitis C and advanced liver disease in real-world clinical practice Liz Highleyman / 24 November 2015 Interferon-free treatment with daclatasvir plus sofosbuvir, with or without ribavirin, led to sustained virological response in a majority of people with genotype 3 hepatitis C virus (HCV) and advanced liver disease treated in ... New AbbVie hepatitis C combination cures 93 to 97% with genotype 3 Keith Alcorn / 19 November 2015 A combination of two experimental direct-acting antivirals developed by AbbVie cured 93 to 97% of people with genotype 3 hepatitis C infection after a 12-week course of treatment, Paul Kwo of Indiana ... Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation Liz Highleyman / 18 November 2015 A co-formulation of sofosbuvir and the pan-genotypic HCV NS5A inhibitor velpatasvir from Gilead Sciences produced sustained response in 99% of people with hepatitis C virus genotypes 1, 2, 4, 5 and 6, ... Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3 Liz Highleyman / 16 November 2015 An 8-week triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 showed a high sustained response rate in a phase 2 study of people with difficult-to-treat hepatitis C virus (HCV), including treatment-experienced people ... Gilead Seeks FDA Approval for Hep C Treatment for All Genotypes Manual Items / 02 November 2015 Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes Gilead press release / 21 September 2015 Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission Bristol-Myers Squibb press release / 15 September 2015 ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive